While significant therapeutic advances have been made against other types of skin cancer, similar progress has not been made against Merkel cell
About Merkel Cell
Carcinoma (MCC) MCC is a rare, aggressive cancer with a disease-associated mortality estimated to be three times that of malignant melanoma and affects approximately 1,600 people per year in the US.
MCPyV was identified in Merkel cell
carcinoma tissue, and evidence suggested that genome integration of MCPyV initiates cell transformation (6).
carcinoma reacts positively for neuroendocrine markers such as synaptophysin and chromogranin, showing a characteristic perinuclear dot-like staining pattern with pan-cytokeratin and CK20 immunohistochemistry (figure 2).
A multicenter French study involving 89 patients with histologically confirmed Merkel cell
carcinoma indicates that individuals with this rare and often aggressive neuroendocrine skin malignancy have an increased prevalence of vitamin D deficiency.
Nonetheless, TTF-1 is still useful for the differential diagnosis of extracutaneous SmCC metastasis to the skin versus primary Merkel cell
carcinoma of the skin because most studies have confirmed that Merkel cell
carcinoma is consistently negative for TTF-1.
Patients with squamous cell carcinoma who were infected with the Merkel cell
virus were about twice as likely to have antibodies for MCV as were people who didn't have cancer, Rollison and colleagues reported in January in Cancer Epidemiology, Biomarkers & Prevention.
carcinoma is a rare, aggressive, malignant cutaneous tumor.
carcinoma (MCC) is a neuroendocrine tumor with a high rate of local recurrence and regional lymph-node metastases (1).
The link between skin cancer Merkel cell
carcinoma and polyomavirus, which is found in birds but can be caught by humans, was discovered by researchers at Israel's Bar-Ilan University.
Research has discovered that Merkel cell
carcinoma, a highly aggressive form of skin cancer, often follows infection by polyomavirus, a virus found in birds but which humans can catch, too.
ImmunoGen's drug, which is currently in mid-stage trials, already has orphan-drug designation for the treatment of Merkel cell
carcinoma, a type of skin cancer, from both the U.